Mutations in gyrase and topoisomerase genes associated with fluoroquinolone resistance in Salmonella serovars from retail meats

详细信息	查看全文 | 推荐本文 |

• 作者：Baowei Yang^a ; Meili Xi^a ; Shenghui Cui^b ; Xiuli Zhang^c ; Jinling Shen^a ; Min Sheng^a ; Dong Qu^a ; Xin Wang^a ; Jianghong Meng^a ; ^d ; ^{Jmeng@umd.edu}
• 关键词：Salmonella ; Quinolone and fluoroquinolone resistance ; DNA gyrase ; Topoisomerase IV ; Mutations
• 刊名：Food Research International
• 出版年：2012
• 期刊代码：53_09639969
• 类别：abs
• 出版时间：March, 2012
• 卷：45
• 期：2
• 页码：935-939
• 文件大小：636 K

摘要

Mutations in gyrase and topoisomerase genes (gyrA, gyrB, parC and parE) were examined among 30 multidrug-resistant (MDR) Salmonella isolates recovered from retail meats using PCR and DNA sequencing analysis. Six isolates had a single gyrA mutation (Ser83 鈫?#xA0;Phe or Ser83 鈫?#xA0;Tyr or Asp87 鈫?#xA0;Asn) with ciprofloxacin (Cip) minimum inhibitory concentrations (MICs) ranging from 0.125 to 0.5 渭g/ml except 1 with 16 渭g/ml. Three isolates had both a gyrA mutation (Ser83 鈫?#xA0;Tyr or Ser83 鈫?#xA0;Phe) and a parC mutation (Ser80 鈫?#xA0;Arg) (Cip MICs, 8 to 16 渭g/ml). Fifteen isolates had both double mutations in gyrA (Ser83 鈫?#xA0;Phe and Asp87 鈫?#xA0;Gly or Asp87 鈫?#xA0;Asn) and a single mutation (Ser80 鈫?#xA0;Arg) in parC (Cip MICs, 8 to 鈮?#xA0;16 渭g/ml). Three had double gyrA mutations (Ser83 鈫?#xA0;Phe, Asp87 鈫?#xA0;Gly or Asp87 鈫?#xA0;Asn), one parC mutation (Ser80 鈫?#xA0;Arg), and 1 parE mutation (Lys428 鈫?#xA0;Gln or Gly442 鈫?#xA0;Ser) (Cip MICs, 8 to 鈮?#xA0;16 渭g/ml). One had double gyrA mutations (Ser83 鈫?#xA0;Phe, Asp87 鈫?#xA0;Gly or Asp87 鈫?#xA0;Asn), one parC mutation (Ser80 鈫?#xA0;Arg), and 2 parE mutations (Lys441 鈫?#xA0;Ile and Asp494 鈫?#xA0;Asn) (Cip MICs, 8 to 鈮?#xA0;16 渭g/ml). Isolates with single gyrA mutations were less resistant to quinolone and fluoroquinolones than those together with additional parC and/or parE mutations in Salmonella. Our findings confirmed the importance of point mutations in gyrase and topoisomerase in reduced susceptibility to quinolone and fluoroquinolones. Mutations in gyrA confer low-level quinolone and fluoroquinolone resistance, while additional gyrA mutation(s) together with parC and/or parE mutations increase the resistance to a high level.